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Abstract
Background: ’Compassionate use’ programmes allow medicinal products that are not authorised, but are in the
development process, to be made available to patients with a severe disease who have no other satisfactory
treatment available to them. We sought to understand how such programmes are regulated in ten European
Union countries.
Methods: The European Clinical Research Infrastructures Network (ECRIN) conducted a comprehensive survey on
clinical research regulatory requirements, including questions on regulations of ‘compassionate use’ programmes.
Ten European countries, covering approximately 70% of the EU population, were included in the survey (Austria,
Denmark, France, Germany, Hungary, Ireland, Italy, Spain, Sweden, and the UK).
Results: European Regulation 726/2004/EC is clear on the intentions of ‘compassionate use’ programmes and
aimed to harmonise them in the European Union. The survey reveals that different countries have adopted
different requirements and that ‘compassionate use’ is not interpreted in the same way across Europe. Four of the
ten countries surveyed have no formal regulatory system for the programmes. We discuss the need for
‘compassionate use’ programmes and their regulation where protection of patients is paramount.
Conclusions: ’Compassionate use’ is a misleading term and should be replaced with ‘expanded access’. There is a
need for expanded access programmes in order to serve the interests of seriously ill patients who have no other
treatment options. To protect these patients, European legislation needs to be more explicit and informative with
regard to the regulatory requirements, restrictions, and responsibilities in expanded access programmes.
Background
’Compassionate use’ programmes in Europe allow a
medicinal product, without marketing authorisation, to
be given to patients with a life-threatening disease when
no alternative authorised treatment exists [1]. The goal
of ‘compassionate use’ is to serve the interests of the
patient.
European Regulation 726/2004/EC legislates for ‘com-
passionate use’ programmes in the European Union [1].
It allows groups of patients with a chronic, seriously
debilitating, or life-threatening disease, without a satis-
factory authorised treatment available, and who cannot
take part in a clinical trial, access to an unlicensed med-
icinal product [1,2]. The medicinal product concerned
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application, or under evaluation in a clinical trial.
‘Compassionate use’ differs from ‘off-label’ use. In ‘off-
label’ use a licensed medicinal product is prescribed for an
indication, or to a patient for which the product is not spe-
cifically licensed, whereas, in ‘compassionate use’ the med-
icinal product is not licensed and not used as a treatment
for any disease. Key differences between ‘compassionate
use’, ‘off-label use’ and randomised clinical trials are sum-
marised in Table 1. An example of a ‘compassionate use’
programme is that for the intravenous formulation of
Tamiflu (oseltamivir phosphate powder for solution for
intravenous infusion) [3,4]. This medicinal product is not
licensed but is available to critically ill adults and children
with pandemic H1N1 or seasonal influenza A or B infec-
tion who did not respond to authorised antivirals or who
cannot take Tamiflu orally [3,4].
Regulation 726/2004/EC states that there is a need for
a common approach across Europe regarding the cri-
teria and conditions for ‘compassionate use’ [1]. The
European Medicines Agency (EMA) has a role in this
harmonisation objective. The EMA’s scientific commit-
tee, the Committee for Medicinal Products for Human
Use (CHMP), can adopt and publish its opinions on the
‘compassionate use’ programme and the patients tar-
geted [1]. In January 2010 the CMPH published its first
opinions on ‘compassionate use’ programmes in the EU
on the EMA website [5]. However, neither Regulation
726/2004/EC nor the CMPH’s recommendations are
binding on the member states [1].
In order to determine if there is a common approach
in Europe, the European Clinical Research Infrastruc-
tures Network (ECRIN) surveyed the nature of the
national legislation and practice in ten European coun-
tries [6], covering approximately 70% of the EU popula-
tion. Here we describe the results and discuss the
impact of ‘compassionate use’ programmes on clinical
practice and clinical intervention research in Europe.
Methods
The ECRIN working group on regulatory requirements
and interaction with competent authorities designed and
conducted an international survey [6]. The survey cov-
ered national regulations and regulatory procedures for
clinical research. The ECRIN working group on regula-
tory requirements and interaction with competent
authorities was composed of two chairpersons, at least
one expert from each European ECRIN country, and an
ECRIN European correspondent (a person trained in
clinical research, working at the national coordination
on the implementation of the ECRIN project) from each
of following countries: Austria, Denmark, France, Ger-
m a n y ,H u n g a r y ,I r e l a n d ,I t a l y ,S p a i n ,S w e d e n ,a n dt h e
United Kingdom. The survey was developed in five
main phases: drafting, consensus, data collection, valida-
tion, and finalising [6].
The two co-chairpersons and two members of the
working group on regulatory requirements and interac-
tion with competent authorities drafted the survey.
Reaching consensus on the questions in the survey took
Table 1 Access to medicinal products, through ‘compassionate use’, ‘off-label’ use and randomised clinical trials
’Compassionate use’
European regulation
Off-label use Randomised clinical trial
Purpose Serves the needs of patients where no
alternative treatment exists
Serves the needs of patients
with an indication other than
that the product is marketed for
Serves the needs of society and future patients and
may benefit some of the included participants
Party
involved
Patients Patients Participants
Disease A life-threatening or chronically or seriously
debilitating disease
Any indication for which the
product is not authorised
Any
Informed
consent
Required in some member states Not required Required
License Medicinal product is not yet licensed Medicinal product is licensed for
other indication(s)
Medicinal product can be licensed and not licensed
Responsible
party
Prescribing physician with approval from the
regulatory authorities
Prescribing physician Sponsor with approval from the regulatory
authorities
Control
group
Without control group Without control group With control group
Data In some member states, some data are
reported to the regulatory authorities
Spontaneous adverse events
may be reported
Outcome measure and adverse event data are
reported to the regulatory authorities
Access to
the
intervention
Medicinal product accessed through the
programme, afterwards those patients can
have access before the product is licensed
Medicinal product available on
prescription
Declaration of Helsinki stipulates that participants
“are entitled to...share any benefits that result from
the trial, for example, access to interventions...”
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involved the whole working group. The drafting and
consensus process took place between November 2006
and February 2007.
The survey was structured according to category and
subcategory of clinical research, with detailed questions
for each category (full survey is available in Additional
file 1). The survey listed 41 questions, with one question
on the specific requirements regarding ‘compassionate
use’ programmes. The format of the survey was an elec-
tronic Word document and it was circulated by email to
three ECRIN transnational working groups as well as
the ECRIN European correspondents in each country
(members are listed in the acknowledgements). Mem-
bers of the working group on regulatory requirements
and interaction with competent authorities responded to
the survey, additionally, members of the working group
on ethics and interaction with ethics committees and
members of the working group on adverse event report-
ing responded to pertinent questions. All answers were
collected, discussed, and validated between March 2007
and October 2008. All ten countries surveyed responded
to the survey. We did not require ethics approval to
perform this questionnaire.
The chairpersons of the working group on regulatory
requirements and interaction with competent authorities
analysed the completed survey and, where needed, held
telephone interviews with the national experts for
further information and explanation of specific answers.
The results of the survey were discussed and finalised
within the working group during numerous teleconfer-
ences (2007-2008) and in two face-to-face ECRIN meet-
ings (19-20 May 2007 and 19-20 May 2008). The results
of the survey were verified by an informal validation
step by representatives from the national competent
authorities of the responding countries.
T h es u r v e yi n c l u d e das e c t i o no n‘compassionate use’
programmes. Here we present the findings relating to
‘compassionate use’ in ten European countries (Austria,
D e n m a r k ,F r a n c e ,G e r m a n y ,H u n g a r y ,I r e l a n d ,I t a l y ,
Spain, Sweden, and the United Kingdom).
The EU Sixth and Seventh Framework Programmes
fund the ECRIN project, but had no role in designing
the questionnaire, in the collection, analysis, and inter-
pretation of data; in the writing of the report; nor in the
decision to submit the paper for publication.
Results
The European Regulation 726/2004/EC legislates for
‘compassionate use’ programmes in the European
Union. It clearly states that patients must have a
chronic, seriously debilitating, or life-threatening disease,
that the medicinal product must be undergoing assess-
ment in a clinical trial or be the subject of a marketing
authorisation application, and that authorisation of the
‘compassionate use’ programme itself is necessary [1].
However, Regulation 726/2004/EC lacks details on the
authorisation procedures, and ultimately allows the
implementation of ‘compassionate use’ programmes to
be governed by individual member states [1].
Results of our survey show that, with the exception of
Hungary, all countries surveyed allow for ‘compassionate
use’ programmes. However, there are more differences
than similarities in ‘compassionate use’ programmes in
Europe. The single element common to all ten countries
was that the responsibility for the ‘compassionate use’
programme lies with the prescribing physician. Four
countries (Hungary, Ireland, Sweden, and the UK) are
currently without formal regulatory systems, and for
those with national legislation on ‘compassionate use’
programmes it is varied in both content and compre-
hensiveness (Table 2). Six of the ten countries surveyed
allow ‘compassionate use’ programmes on a ‘named/
individual patient’ basis (Austria, Denmark, France, Italy,
Spain, and the UK), only three countries (Austria,
France, and Spain) specify that ‘compassionate use’ pro-
grammes must be outside clinical trials, the opinion of
the ethics committee is only sought in two countries
(Italy and Spain (and in some UK hospitals)). The con-
tents and requirements of the application for authorisa-
tion varies in all the countries surveyed and in most
countries the outcomes of the ‘compassionate use’ pro-
gramme do not need to be reported to the regulatory
authorities. Differing interpretations and regulatory
requirements result from Regulation 726/2004/EC not
being explicit and because the Regulation allows indivi-
dual member states to govern the programmes
nationally.
National legislation and practice
In Austria, national regulations for ‘compassionate use’
for groups of patients, in accordance with the European
Regulation 2004/726/EC, are currently under prepara-
tion. As an alternative, ‘named patient use’ could be uti-
lised [7]. ‘Named patient use’ allows a physician to give
ap a t i e n tw i t has e v e r ec o n d i t i o nam e d i c i n a lp r o d u c t
which has no market approval in Austria. The treating
physician has full responsibility. This can only be done
on an individual basis, ie, the name of the patient must
be known [7]. ‘Named patient use’ cannot be used in a
clinical trial with anonymous patients.
In Denmark, it is possible to carry out ‘compassionate
use’ studies. ‘Compassionate use permits’ a r eo n l yp e r -
mitted for a specific treatment for an individual patient
[8]. In special cases the Danish Medicines Agency can
authorise the dispensing or sale of a medicinal product,
eg, for life threatening diseases for which there are no
well-documented treatment options. The treating doctor
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ish Medicines Agency. This is an application to dispense
non-authorised medicinal products. The application
includes the description of treatment, the expected
duration of treatment, product information, scientific lit-
erature or other information about effects, adverse reac-
tions, copy of medical records and information about
planned monitoring of the course of the disease [8]. If
accepted, the applicant receives authorisation. The appli-
cant must notify the pharmacy and include a copy of
the authorisation with the prescription. The treating
physician is obliged to report back to the Danish Medi-
cines Agency. Adverse reactions related to the medicinal
product must be reported to the Danish Medicines
Agency. However, the amount of reporting has been
reduced to accommodate an increase in requests for
‘compassionate use permits’,e g ,a g ea n ds e xo ft h e
patient no longer need to be reported [8].
In France, use of medicinal products which do not have
marketing authorisation and which is outside the context
of a clinical trial is dependent on prior ‘temporary
authorisation for use’ (ATU) being granted by the French
Health Products Agency (Afssaps) [9,10]. ATU permits
are granted as a discretionary, exceptional, and tempor-
ary measure, when the following conditions are met: the
treatment, prevention, or diagnosis of serious or rare dis-
eases; an absence of a suitable therapeutic alternative
(medicinal product or other) available in France and
when the benefit/risk ratio of the medicinal product is
presumed to be positive. The use of these medicinal pro-
ducts is authorised by Afssaps, for a limited period of
time. In practice, there are two types of temporary
authorisations for use. Firstly, the ‘nominative temporary
authorisation for use’, issued for a named patient, at the
request of and under the responsibility of the prescribing
physician. This type of ‘temporary authorisation for use’
concerns medicinal products of which the efficacy/safety
ratio is presumed to be favourable in the light of the data
available. Secondly, the ‘cohort temporary authorisation
for use’, which concerns a group or sub-group of partici-
pants, treated and monitored according to criteria fully
defined in a protocol for therapeutic use and information
collection. A ‘cohort temporary authorisation for use’ is
issued at the request of the holder of the licensing rights,
who commits to submit a marketing authorisation appli-
cation within a determined time limit.
Table 2 Summary of ‘compassionate use’ regulations in ten European countries
Country ’Compassionate use’ Responsibility Authorising agency Reporting
Austria Termed ‘Named patient use’
Treatment of individuals
Separate from clinical trials
Treating physician N/A No
Denmark Termed ‘Compassionate use permit’
Treatment of individuals
Consent to disclose health data
required
Treating physician Danish Medicines Agency (DMA) Adverse events reported to the
DMA
France Termed ‘Temporary authorisation for
use’ for individuals, or ‘Cohort
temporary authorisation for use’
Separate from clinical trials
For ‘nominative’ use the
prescribing physician, for
‘cohort’ use the license
holder
Agence Française de sécurité
sanitaire des produits de santé
(Afssaps)
All adverse reactions. Periodic
report for ‘temporary
authorisation for use’
programmes.
Germany National legislation and guidelines
Informed consent required
’Responsible person’ Bundesinstitut für Arzneimittel
und Medizinprodukte (BfArM) or
Paul-Ehrlich Institut (PEI)
Serious adverse events reported
to authorising agency within 15
days
Hungary No specific legislation N/A N/A N/A
Ireland The product must be between a
phase III trial and marketing
authorisation
Guidelines
Prescribing physician Irish Medicines Board (IMB) No
Italy Termed ‘Compassionate use’ for
individuals
Informed consent required
Treating physician Ethics committee No
Spain Termed ‘Compassionate use’ for
individuals
Informed consent required
Separate from clinical trials
Treating physician Agencia Española de
medicamentos y productes
sanitarios (AEMPS)
Efficacy and adverse events
reported to AEMPS
Sweden Guidelines N/A Medical product agency (MPA) N/A
UK Termed ‘compassionate use’ or
‘expanded access’ using ‘specials’ for
individual patients
Guidelines
Prescribing physician Medicines and Healthcare
products Regulatory Agency
(MHRA)
Serious adverse reactions
reported to MHRA
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medicinal products were introduced into legislation with
the 14th amendment of the German Medicines Act
(AMG) and was updated by the 15th amendment effec-
tive from July 2009 [11]. Section 21(2) of the AMG
states that under the provisions in Article 83 of Eur-
opean Regulation 726/2004 EC medicinal products
which are made available to patients with a disease
which leads to severe disability or which is life-threaten-
ing and who cannot be satisfactorily treated with an
approved medicinal product, do not require marketing
authorisation [11]. The 15th amendment also stipulates
that dispensing of the medicinal products in ‘compassio-
nate use’ programmes must be free of charge and
exempts these products from the prescription medicine
pharmacy chain of distribution [11]. In July 2010, a new
ordinance set out precise regulations regarding the duty
of the responsible person to notify the competent
authority, the need to secure approval from the compe-
tent authority, patient informed consent, reporting ser-
ious adverse events to the competent authority, and
public availability of information about the main charac-
teristics of the programmes [12].
In Hungary there is neither regulation nor implemen-
tation of ‘compassionate use’ programmes.
In Ireland, currently there is no system regulating
‘compassionate use’ programmes, however, ‘compassio-
nate use’ programmes can fall under the Irish clinical
trial regulations SI 190 of 2004 or SI 540 of 2007 [13].
Clinical trial regulations SI 190 of 2004 require all inves-
tigational medicinal product studies to be authorised by
the Irish competent authority prior to the start of the
trial. SI 540 of 2007 Schedule I, point 5, paragraph 2
exempts a product without a marketing authorisation in
Ireland from being imported, however, it can be pre-
scribed by a medical doctor, but responsibility of the
oversight of the product is that of the prescriber (medi-
cal doctor) [13]. The Irish competent authority has
established a statutory notification system for use of
unauthorised medicines. It is the responsibility of the
wholesaler and manufacturer to notify the Irish compe-
tent authority if they receive unauthorised medicines
[14].
In Italy, the ‘compassionate use’ of a medicinal pro-
duct used in non-authorised conditions in a single
patient in exceptional circumstances is allowed and is
regulated by the Ministry of Health Decree May 8, 2003
and by the Legislative Decree April 24, 2006 n. 219
[15,16]. The request for ‘compassionate use’ pro-
grammes should be made by the physician who assumes
responsibility of administration of the product to the
patient. An authorisation should be requested from the
ethics committee, and a special informed consent should
be prepared.
In Spain, ‘compassionate use’ is defined as the pre-
scription of a medicinal product used in a non-
authorised condition in isolated patients outside the
context of a clinical trial, and under the physician’s
responsibility. An informed consent, a clinical report, a
centre authorisation, and the Spanish Agency for Medi-
cines and Medical Devices (Agencia española de medi-
camentos y productos sanitarios, AEMPS) authorisation
are required. The physician should notify the results and
adverse reactions to the AEMPS. ‘Compassionate use’
programmes will be allowed in the period between the
application for approval and the decision on market
authorisation of the medicinal product [17].
In Sweden, there is no system regulating ‘compassio-
nate use’ programmes. In general, only commercial
sponsors can offer ‘compassionate use’ programmes and
the Swedish Medical Products Agency provisions
explain in what situation this is possible. Instead it may
be possible to prescribe the study drug after disconti-
nuation of study on a participant-by-participant basis.
In the UK, in the case of clinical trials involving med-
icinal products or medical devices, the treatment should
be extended after the end of the trial if the participant is
benefitting fro the product or device, this is known as
‘expanded access’. Outside clinical trials and subject to
certain conditions, unlicensed medicinal products (’spe-
cials’) can be manufactured and supplied to individual
patients in order to meet the needs of some patients
who cannot be treated with licensed medicinal products
[18]. The product is for use by individual patients on
the prescriber’s direct personal responsibility, essential
records must be kept, and serious adverse drug reac-
tions reported to the Medicines and Healthcare pro-
ducts Regulatory Agency (MHRA) [18]. The MHRA has
issued a guideline on unlicensed medicinal products for
individual patients [19]. Ethical review of ‘compassionate
use’ is available in some UK healthcare trusts through a
‘clinical ethics committee’, but this is not nationwide
[20]. A regional body of the UK National Health Service,
The Kent and Medway Area Prescribing Committee, has
issued additional guidelines for access to unlicensed
investigational drugs outside of clinical trials. The gui-
dance includes that the prescriber believes that the risk/
benefit profile of the new drug is likely to be favourable
to the patient, the prescriber has explained to the
patient or carer that the medicine is unlicensed, and the
prescriber obtains and documents the patient’sc o n s e n t
to treatment before prescribing [21].
Discussion
Under the European Regulation 726/2004/EC legislation
for ‘compassionate use’ programmes, eligible patients
can be granted access to a medicinal product, which is
not licensed [1]. One aim of Regulation 726/2004/EC is
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programmes across Europe. In order to understand how
‘compassionate use’ programmes are regulated, and to
ascertain if the desired common approach is being
achieved in Europe, ECRIN surveyed ten European
countries representing approximately 70% of the
EU population [6]. We found significant differences
in the national regulations for ‘compassionate use’
programmes.
Through performing the survey and examining the
pertinent legislation, it is clear that ‘compassionate use’
is not a suitable term for these programmes. ‘Compas-
sion’ describes the wish to relieve suffering, a fundamen-
tal principle throughout healthcare. Accessing medicinal
products with little knowledge of their benefit or harm
should not be labelled as the most compassionate strat-
egy. Relief of suffering is not always achieved through
intervening and certainly does not come through caus-
ing more harm than good. We therefore prefer the term
‘expanded access’,a su s e di nt h eU S A[ 2 2 ] .I td e s c r i b e s
a key element of the programme, i.e., that a medicinal
p r o d u c ti sm a d em o r ew i d e l ya v a i l a b l eb e f o r ei th a s
obtained market authorisation. We will use the term
expanded access for the rest of the discussion.
The major weakness of this survey is that the results
from 10 member states may not adequately reflect the
situation across Europe. However, nine of the ten coun-
tries we surveyed do have national legislation and
requirements for expanded access programmes; this
strong trend may be indicative of the situation in other
European countries. For example, Switzerland, although
not bound by the EU Regulation, does have legislation
for national expanded access programmes [23]. The
national competent authority (Swissmedic-Swiss Agency
for Therapeutic Products) authorises the programmes
under the conditions that the disease is life threatening,
the programme is compatible with the protection of
health, a significant therapeutic benefit is expected and
no comparable medicine exists [23]. Reporting adverse
events to Swissmedic is mandatory [24]. The Swiss
requirements illustrate that the results of our survey
may be quite representative of the European picture.
European legislation - let’s go further
The results show that there are more differences than
similarities in expanded access programmes in Europe;
it appears that the desired common approach is lacking.
There are inherent challenges in striving for harmonisa-
tion in 27 member sates, each with differing health care
systems, however, the differences in the availability of
expanded access programmes and in the protection of
the patient remain in part because Regulation 726/2004/
EC allows national expanded access programmes to be
governed by individual member state legislation [1].
This undermines the expectations of European patients
and citizens.
Although Regulation 726/2004/EC clearly states that
authorisation of expanded access programmes is neces-
sary, it does not describe any aspects of the required
content for the authorisation application nor the author-
isation process, and the responsibilities of the prescrib-
ing physician, national competent authorities, and the
product manufacturer are ambiguous. To achieve a
common approach, European legislation needs to be
more explicit and rule that: authorisation requires evi-
dence from a randomised clinical trial of greater benefit
than harm; competent authorities assess the intervention
and independent ethics committees assess the risk to the
patient (as is practised in Spain and in some UK hospi-
tals); authorisation is independent of the product manu-
facturer; an open-access list of authorised programmes
is mandatory; safety and efficacy data are reported to
the regulatory authorities (as is practised in Denmark,
France, Germany, and Spain); depositing the results of
the programmes in an open-access database is necessary;
and patient information with full informed consent pro-
c e d u r e si sr e q u i r e d .I m p r o v ed legislation must then
apply to all medicinal interventions including surgery
and medical devices and be binding on all member
states.
The Food and Drug Administration (FDA) has
recently implemented improvements, similar to those
we present here, to the US regulations on expanded
access which include the need for informed consent,
assessment by an independent review board, and the
reporting of patient outcomes and adverse effects to the
FDA [22].
A public register of the CMPH’so p i n i o n so fs p e c i f i c
expanded access programmes on the EMA website was
launched in January 2010 and is a positive step towards
developing a common approach in Europe [5].
The basis of these additional requirements is to better
serve and protect patients, although it is possible that
stricter requirements could lengthen the waiting time
for access to new interventions. On the opposite, shar-
ing information between the regulatory authorities and
the EMA on authorisations and safety and efficacy
records should accelerate decision making and access.
Expanded access cannot replace clinical trials
Expanded access programmes do not reliably inform us
of the benefits and harms of an intervention and cannot
replace randomised clinical trials (Table 1) [25,26]. A
randomised clinical trial tests a medical intervention
against a control, the purpose of which is to improve
healthcare for society and future patients. Blurring the
lines between expanded access and clinical trials risks
that expanded access programmes are undertaken as an
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ducts instead of conducting randomised clinical trials.
When this happens, the safeguards inherent to clinical
trials, eg, having a control group, securing insurance to
protect the patients, reporting all adverse events, report-
ing the results, etc. are all circumvented.
Regulation 726/2004/EC separates expanded access
and clinical trials, but many member states do not. Only
the Austrian, French, and Spanish national legislation
clearly states that expanded access programmes must be
conducted separately from clinical trials. Expanded
access programmes and clinical trials must be separated,
firstly to protect patients from exploitation, and sec-
ondly so that both the needs of the seriously ill and the
needs of society can be best served.
There are other situations where patients can access
unlicensed medicinal products: phase I study partici-
pants and clinical trial participants. Some types of phase
I studies enrol patients with a serious or terminal dis-
ease without treatment options (principally cancer).
Although the principal purpose of phase I studies is to
assess the safety of the medicinal product, the partici-
pants of phase I studies are afforded greater protection
than those in the expanded access programme through
the regulatory requirements needed for any clinical trial
(eg, ethical review, informed consent, insurance). For
any type of clinical trial, according to the Declaration of
Helsinki, when trial participants benefit from a clinical
trial intervention, they should have access to that inter-
vention after the trial has finished [27]. Furthermore, if
the intervention is potentially beneficial to patients out-
side the clinical trial with a chronic, seriously debilitat-
ing, or life-threatening disease, without a satisfactory
authorised treatment available, then this intervention
should be made available to them through an expanded
access programme.
Expanded access is for patients
The purpose of expanded access is to serve the needs of
patients. For patients with serious and life-threatening
diseases without sufficient treatment options there is an
absolute need for expanded access programmes. How-
ever, expanded access involves unknown risks. Patients
have the right to make informed judgements about taking
part in an expanded access programme, just as clinical
trial participants do. This must involve informed consent
procedures where all options, including that of palliative
care or no treatment, are presented objectively, and for
those who cannot give their own consent, surrogate con-
sent should be possible. The newly available information
from the EMA website is open-access and contributes to
informing patients about expanded access programmes
in general and about specific programmes [5]. It is
paramount that informed consent procedures are imple-
mented in Europe.
Conclusions
’Compassionate use’ is a misleading term and should be
replaced with ‘expanded access’. To protect patients,
European legislation needs to be more explicit and
informative with regard to the regulatory requirements,
restrictions, and responsibilities in expanded access pro-
grammes. With increasing demand from patients [25,26]
expanded access programmes must not be left in a grey-
l e g i s l a t i v ea r e aa st h e yc o n c e r ns o m eo ft h em o s tv u l -
nerable in society.
Additional material
Additional file 1: Copy of the full ECRIN questionnaire on
regulatory requirements in clinical research.
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